Render Target: SSR
Render Timestamp: 2024-11-14T23:07:47.658Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:55:34.527
Product last modified at: 2024-10-29T19:45:09.497Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

TRA-1-81 (TRA-1-81) Mouse mAb #4745

Filter:
  • IHC
  • IF
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 200-400
    Source/Isotype Mouse IgM
    Application Key:
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunohistochemistry (Paraffin) 1:100
    Immunofluorescence (Immunocytochemistry) 1:1000
    Flow Cytometry (Fixed/Permeabilized) 1:1600
    Flow Cytometry (Live) 1:1600

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TRA-1-81 detects endogenous levels of TRA-1-81 antigen.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with human embryonal carcinoma 2102Ep cl.2A6 cells.

    Background

    TRA-1-60 and TRA-1-81 antibodies detect antigens present on the surface of human stem, teratocarcinoma, and embryonic germ cells (1). TRA-1-60(S) reacts with a neuraminidase sensitive epitope of a proteoglycan (2,3), while TRA-1-81 reacts with a neuraminidase insensitive epitope on the same antigen. Recently this antigen has been proposed to be a form of the protein podocalyxin (4). TRA-1-60 is also detected in the serum of patients with germ cell tumors (5,6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.